ORPHA:180
Choroideremia
Also known as: CHM · Tapetochoroidal dystrophy
Query health: suspect — Only one of 2 strategies returned hits (phrase).
Publications
2,469
Trials
19
Interventional, condition-specific
Researchers
1,125
Distinct authors in sample
Gene link
CHM
Definitive
Readiness
3/6
Stages with a signal
Clinical definition (Orphanet)
Choroideremia (CHM) is an X-linked chorioretinal characterized by degeneration of the choroid, retinal pigment epithelium (RPE) and retina.
How rare: 1-9 / 100 000 — about one to nine people per hundred thousand.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0010557
- MeSH:D015794
- OMIM:303100
- UMLS:C0008525
- NCIT:C34469
Additional Mondo synonyms (2)
choroideremia · progressive choroidal atrophy
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
3/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedPresent
Definitive — CHM
- LiteraturePresent
2,469 matched papers (1,370 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPresent
19 matched on ClinicalTrials.gov
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Yes — we know a specific gene responsible (CHM).
GenCC classification: Definitive.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
2,469
2,469 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
2,469 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
1,370 in the last 10 years · low confidence
Phrase hits: 2,469 · MeSH hits: 0
Who's working on it?
1,125
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01MacLaren RE27 papers · 2026
Nuffield Laboratory of Ophthalmology, Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
Papers in Europe PMC - 02Jolly JK14 papers · 2025
Nuffield Laboratory of Ophthalmology, Nuffield Department of Clinical Neurosciences, University of Oxford, NIHR Oxford Biomedical Research Centre, Oxford, UK.
Papers in Europe PMC - 03Taylor LJ14 papers · 2025
Nuffield Laboratory of Ophthalmology, Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
Papers in Europe PMC - 04Ayton LN9 papers · 2025
Department of Optometry and Vision Sciences, The University of Melbourne, Melbourne, Victoria, Australia; Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, Melbourne, Victoria, Australia; Ophthalmology, Department of Surgery, The University of Melbourne, Melbourne, Victoria, Australia. Electronic address: layton@unimelb.edu.au.
Papers in Europe PMC - 05Josan AS9 papers · 2025
Nuffield Laboratory of Ophthalmology, Nuffield Department of Clinical Neurosciences, University of Oxford, NIHR Oxford Biomedical Research Centre, Oxford, UK.
Papers in Europe PMC - 06Gocuk SA8 papers · 2025
Department of Optometry and Vision Sciences, The University of Melbourne, Melbourne, Victoria, Australia; Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, Melbourne, Victoria, Australia; Ophthalmology, Department of Surgery, The University of Melbourne, Melbourne, Victoria, Australia.
Papers in Europe PMC - 07Edwards TL7 papers · 2025
Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, Melbourne, Victoria, Australia; Ophthalmology, Department of Surgery, The University of Melbourne, Melbourne, Victoria, Australia.
Papers in Europe PMC - 08Cehajic-Kapetanovic J6 papers · 2024
Oxford Eye Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 9DU, UK.
Papers in Europe PMC - 09Lam BL6 papers · 2025
Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL, USA.
Papers in Europe PMC - 10
Clinical research
Is a treatment being tested?
19
interventional trials for this specific condition
19 interventional trials matched this specific condition name; none in our sample are currently recruiting.
Data as of 27 July 2026
19 interventional trials — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 94.2th percentile).
low confidence · 94.2th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
19 interventional trials matched after quoted-phrase search and title/condition post-filter.
No currently recruiting studies in the matched set. Open the same search on ClinicalTrials.gov.
Observational and natural-history studies
9 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT06375239·RECRUITING·Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal Degeneration
Conditions: Retinitis Pigmentosa · Choroideremia · Stargardt Macular Dystrophy · Stargardt Disease·Matched via name phrase
- NCT05158049·ENROLLING BY INVITATION·Longitudinal Study of a Bionic Eye
Conditions: Retinitis Pigmentosa · Choroideremia·Matched via name phrase
- NCT02435940·RECRUITING·Inherited Retinal Degenerative Disease Registry
Conditions: Eye Diseases Hereditary · Retinal Disease · Achromatopsia · Bardet-Biedl Syndrome·Matched via name phrase
- NCT01866371·RECRUITING·High Resolution Retinal Imaging
Conditions: Stargardts · Retinitis Pigmentosa · Age-related Macular Degeneration · Choroideremia·Matched via name phrase
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Choroideremia" OR "Tapetochoroidal dystrophy" OR "progressive choroidal atrophy"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Choroideremia" OR "Tapetochoroidal dystrophy" OR "progressive choroidal atrophy" OR "CHM"
Recall-expansion terms: CHM
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 19 interventional · 9 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: suspect — strategies attempted: phrase, recall-expansion; with hits: phrase
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: CHM
Confidence reasoning
- Preferred label is short or not clearly distinctive
- 1 synonym(s) dropped by stoplist (may under-count)
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-26T12:47:08.599Z
